Evidence map›Paper›PMID 32121045›Full record

ArticleBiology2020

Retinoprotective Effect of 2-Ethyl-3-hydroxy-6-methylpyridine Nicotinate.

Anna Peresypkina, Anton Pazhinsky, Lyudmila Danilenko, Sergey Lugovskoy, Mikhail Pokrovskii, Evgeniya Beskhmelnitsyna, Nikolai Solovev, Anna Pobeda, Mikhail Korokin, Elena Levkova and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. New Insights for nicotinamide: Metabolic disease, autophagy, and mTOR.Frontiers in bioscience (Landmark edition) · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Anna PeresypkinaDepartment of Pharmacology and Clinical Pharmacology, Institute of Medicine, Belgorod State National Research University, Belgorod 308015, Russia.
Anton PazhinskyDepartment of Pharmacology and Clinical Pharmacology, Institute of Medicine, Belgorod State National Research University, Belgorod 308015, Russia.
Lyudmila DanilenkoDepartment of Pharmacology and Clinical Pharmacology, Institute of Medicine, Belgorod State National Research University, Belgorod 308015, Russia.ORCID 0000-0001-6101-8712
Sergey LugovskoyDepartment of Pharmacology and Clinical Pharmacology, Institute of Medicine, Belgorod State National Research University, Belgorod 308015, Russia.
Mikhail PokrovskiiDepartment of Pharmacology and Clinical Pharmacology, Institute of Medicine, Belgorod State National Research University, Belgorod 308015, Russia.
Evgeniya BeskhmelnitsynaDepartment of Pharmacology and Clinical Pharmacology, Institute of Medicine, Belgorod State National Research University, Belgorod 308015, Russia.
Nikolai SolovevDepartment of Pharmacology and Clinical Pharmacology, Institute of Medicine, Belgorod State National Research University, Belgorod 308015, Russia.
Anna PobedaDepartment of Pharmacology and Clinical Pharmacology, Institute of Medicine, Belgorod State National Research University, Belgorod 308015, Russia.
Mikhail KorokinDepartment of Pharmacology and Clinical Pharmacology, Institute of Medicine, Belgorod State National Research University, Belgorod 308015, Russia.
Elena LevkovaDepartment of Pharmacology and Clinical Pharmacology, Institute of Medicine, Belgorod State National Research University, Belgorod 308015, Russia.
Victoria GubarevaDepartment of Pharmacology and Clinical Pharmacology, Institute of Medicine, Belgorod State National Research University, Belgorod 308015, Russia.
Liliya KorokinaDepartment of Pharmacology and Clinical Pharmacology, Institute of Medicine, Belgorod State National Research University, Belgorod 308015, Russia.
Olga MartynovaResearch Institute of Pharmacology of Living Systems, Belgorod State National Research University, Belgorod 308015, Russia.
Vladislav SoldatovResearch Institute of Pharmacology of Living Systems, Belgorod State National Research University, Belgorod 308015, Russia.
Vladimir PokrovskiiResearch Institute of Pharmacology of Living Systems, Belgorod State National Research University, Belgorod 308015, Russia.
Belgorod National Research University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An important task of pharmacology is to find effective agents to improve retinal microcirculation and resistance to ischemia. The purpose of the study is to pharmacologically evaluate the retinoprotective effect of 2-ethyl-3-hydroxy-6-methylpyridine nicotinate in a rat model of retinal ischemia-reperfusion. A retinal ischemia-reperfusion model was used, in which an increase in intraocular pressure (IOP) to 110 mmHg was carried out within 30 min. The retinoprotective effect of 2-ethyl-3-hydroxy-6-methylpyridine nicotinate at a dose of 3.8 mg/kg, in comparison with nicotinic acid at a dose of 2 mg/kg and emoxipine at a dose of 2 mg/kg, was estimated by the changes in the eye fundus during ophthalmoscopy, the retinal microcirculation level with laser Doppler flowmetry (LDF), and electroretinography (ERG) after 72 h of reperfusion. The use of 2-ethyl-3-hydroxy-6-methylpyridine nicotinate prevented the development of ischemic injuries in the fundus and led to an increase in the retinal microcirculation level to 747 (median) (lower and upper quartiles: 693;760) perfusion units (

Indexed as

2-ethyl-3-hydroxy-6-methylpyridine nicotinateelectroretinographylaser Doppler flowmetryophthalmoscopyretinal ischemia

Identifiers

PMID32121045
PMCPMC7150877
OpenAlexW3008648719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.